Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Nordisk
since
auto-detected in 451 stories
63 days ago
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
90 days ago
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
found
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
2 months ago
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
3 months ago
Novo Nordisk shares jump up on latest weight loss trial results
People treated with amycretin lost up to 22% of their body weight after 36 weeks
4 months ago
Novo Nordisk’s drug stumble leaves it suddenly much slimmer
Market will never be winner takes all given that different patients will have different requirements
|← first ← previous page 4 of 5 next → last →|